Protein Summary
5' to 3' RNA helicase contributing to UPF1 mRNA target degradation by translocation along 3' UTRs (PubMed:24726324). Required for microRNA (miRNA)-mediated gene silencing by the RNA-induced silencing complex (RISC). Required for both miRNA-mediated translational repression and miRNA-mediated cleavage of complementary mRNAs by RISC (PubMed:16289642, PubMed:17507929, PubMed:22791714). In cooperation with FMR1, regulates miRNA-mediated translational repression by AGO2 (PubMed:25464849). Restricts retrotransposition of long interspersed element-1 (LINE-1) in cooperation with TUT4 and TUT7 counteracting the RNA chaperonne activity of L1RE1 (PubMed:30122351, PubMed:23093941). Facilitates LINE-1 uridylation by TUT4 and TUT7 (PubMed:30122351). Required for embryonic viability and for normal central nervous system development and function. Plays two critical roles in early brain development: suppresses retroelements in the nucleus by directly inhibiting cDNA synthesis, while regulates cytoskele ...more
- ENST00000357443
- ENSP00000350028
- ENSG00000155363
- ENST00000369645
- ENSP00000358659
- ENST00000413052
- ENSP00000399797
- KIAA1631
- gb110
- fSAP113
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
interacting protein | 0.99 | ||
virus perturbation | 0.97 | ||
molecular function | 0.95 | ||
transcription factor binding site profile | 0.88 | ||
transcription factor perturbation | 0.8 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 65.43 (req: < 5)
Gene RIFs: 30 (req: <= 3)
Antibodies: 156 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 65.43 (req: >= 5)
Gene RIFs: 30 (req: > 3)
Antibodies: 156 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 14
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0